Dynavax stock drops, pops with massive volatility
Well, not all news out of China is bad this week. Since the last post on the subject my DVAX story saw a massive drop (on bad COVID related news, which I held without a thought of selling) and today, on positive COVID Adjuvant news a massive pop after release of trial results from China’s Clover Biopharma (with no thought of selling either, pending the markets and subject to change as always).
The COVID stuff is responsible for all the volatility while the company slowly progresses with its Hepatitis vaccine commercialization, which was my long-term buy rationale. I guess I have to properly value and account for the COVID stuff, because up to now I’ve been ignoring it since it is not the reason I bought the stock. Plus I hate hype. But it feels like the market thinks there is real fundamental stuff going on in the COVID realm as well, so…
For “best of breed” top down analysis of all major markets, subscribe to NFTRH Premium, which includes an in-depth weekly market report, detailed market updates and NFTRH+ dynamic updates and chart/trade setup ideas. Subscribe by PayPal or credit card using a button on the right sidebar (if using a mobile device you may need to scroll down). Keep up to date with actionable public content at NFTRH.com by using the email form on the right sidebar. Follow via Twitter @NFTRHgt.
